Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 366.2 INR -1.82% Market Closed
Market Cap: ₹488.9B

Operating Margin

9.9%
Current
Declining
by 1.4%
vs 3-y average of 11.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
9.9%
=
Operating Income
₹16.2B
/
Revenue
₹164.8B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
9.9%
=
Operating Income
₹16.2B
/
Revenue
₹164.8B

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Biocon Ltd
NSE:BIOCON
488.9B INR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.3B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

In line with most companies in India
Percentile
60th
Based on 5 437 companies
60th percentile
9.9%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Biocon Ltd
Glance View

In the bustling world of biotechnology, Biocon Ltd. stands as a beacon of innovation, rooted in its Indian origins yet extending its influence globally. Founded in 1978 by Kiran Mazumdar-Shaw, a visionary with a degree in fermentation science, Biocon began its journey as a maker of enzymes before transforming into a formidable force in biopharmaceuticals. This transformation was driven by the company's emphasis on research and development, leading to groundbreaking advancements in biosimilars, generics, and novel biotherapeutics. These products cater to critical areas such as oncology, diabetes, and autoimmune diseases. The company's success hinges on its ability to blend scientific rigor with entrepreneurial flair, enabling it to deliver high-quality, cost-effective solutions in a market traditionally dominated by Western giants. Biocon's revenue model is intricately woven from various strands of its expansive portfolio. A significant chunk emerges from its biologics division, where it manufactures biosimilars that serve as cost-friendly alternatives to expensive biologic drugs. Simultaneously, the company capitalizes on its expertise in small molecule APIs and branded formulations, which are integral to its generics business. Furthermore, collaborations and partnerships with global pharmaceutical companies amplify its reach, facilitating market access and regulatory navigation. Through these strategic undertakings, Biocon not only bolsters its financial performance but also reinforces its commitment to enhancing healthcare affordability and accessibility across the globe.

BIOCON Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
9.9%
=
Operating Income
₹16.2B
/
Revenue
₹164.8B
What is Biocon Ltd's current Operating Margin?

The current Operating Margin for Biocon Ltd is 9.9%, which is below its 3-year median of 11.3%.

How has Operating Margin changed over time?

Over the last 3 years, Biocon Ltd’s Operating Margin has decreased from 12% to 9.9%. During this period, it reached a low of 8.9% on Dec 31, 2024 and a high of 14.6% on Mar 31, 2023.

Back to Top